BioNTech, Hands

BioNTech Hands Roche Its Share of the Bill and Pays Up for a Faster FDA Lane

Published on 11/17/2026 at 14:41 | Editorial boerse-global.de
BioNTech moves partnered oncology R&D costs to Roche/Genentech from 2027 and agrees to pay $205 million for a Scholar Rock FDA priority review voucher.
BioNTech Hands Roche Its Share of the Bill and Pays Up for a Faster FDA Lane Illustration mit AI erstellt.

BioNTech has moved on two fronts at once: shifting the cost burden of a partnered oncology programme onto Roche/Genentech, and agreeing to spend $205 million in cash on a regulatory fast-pass from Scholar Rock.

The cost arrangement, disclosed on 3 November, follows BioNTech's exercise of an option in its collaboration with Roche/Genentech. Under the terms, future research and development expenses are in principle to be allocated to Roche/Genentech from 1 January 2027. BioNTech retains the right to licensing payments should the programme be successfully developed and marketed. The ongoing PDAC study will continue as planned, the company said.

Separately, the November agreement with Scholar Rock covers a Priority Review Voucher from the US Food and Drug Administration. The $205 million payment is tied to a future filing rather than any approval already granted — BioNTech intends to deploy the voucher to support an upcoming application for an asset from its late-stage oncology pipeline. Completion remains subject to customary closing conditions, including clearance under the Hart-Scott-Rodino process.

Should investors sell immediately? Or is it worth buying BioNTech?

Third-Quarter Figures and a Raised Floor

The deals land alongside third-quarter 2026 results showing revenue of €1.29 billion and an IFRS net profit of €184.5 million. Over the first nine months of 2026, revenue reached €1.51 billion, while the bottom line showed a net loss of €1.17 billion. BioNTech attributed the softer top line chiefly to lower demand for its COVID-19 vaccines, as anticipated.

Guidance for the full year was adjusted at the lower end: the company now expects revenue of between €1.7 billion and €1.9 billion, with the upper bound left untouched. Forecasts for adjusted research and development costs, as well as for sales and administrative expenses, were reaffirmed.

Ahead of the open, the stock was down 0.5% pre-market. No link between that move and either the voucher agreement or the quarterly figures has been established.

Ad

BioNTech Stock: New Analysis - 17 November

Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated BioNTech analysis...

Disclaimer...
en | US09075V1026 | BIONTECH | boerse | 70527194 |